ArticleFrontiers in oncology2025
Prospective evaluation of mpMRI-derived nomograms for detecting prostate cancer in PI-RADS v2.1 upgraded and non-upgraded lesions.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Limited data exist on the performance of Prostate Imaging Reporting and Data System (PI-RADS) v2.1 upgraded and non-upgraded lesions, both alone and in combined with multiparametric MRI (mpMRI) features, for prostate cancer detection. Objective: To evaluate the rates of prostate cancer (PCa) and clinically significant prostate cancer(csPCa) rates in PI-RADS v2.1 upgraded and non-upgraded lesions, and to identify mpMRI features that improve detection accuracy. Methods: This study included men who underwent mpMRI and ultrasound-guided (US-guided) biopsy from March 2023 to April 2024. MRI scans were prospectively evaluated according to PI-RADS v2.1. MpMRI features were extracted from lesion contours, including three-dimensional maximum diameter, lesion volume, sphericity, surface-to-volume ratio (SVR), T Results: A total of 94 patients(mean age, 65.7 years) with 234 lesions were included. Significant differences were observed between upgraded and non-upgraded PI-RADS 4 lesions( Conclusion: PI-RADS v2.1 upgrading rules improve cancer detection in the TZ, but upgrading PI-RADS category 3 lesions in the PZ may lead to unnecessary biopsies. MpMRI-based nomograms enhance predictive accuracy for both PCa and csPCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.